Literature DB >> 2977606

Mechanism of action of prothymosin alpha in the human autologous mixed lymphocyte response.

C N Baxevanis1, G J Reclos, M Economou, P Arsenis, A Katsiyiannis, K Seferiades, G Papadopoulos, O Tsolas, M Papamichail.   

Abstract

Prothymosin alpha(Prot alpha), an immunologically active polypeptide derived initially from rat thymus, and now pig thymus, was tested for its effect on autoantigen-induced human T cell proliferation in vitro. Pig ProT alpha was found to enhance the autologous mixed lymphocyte response (auto-MLR). Optimum enhancement was achieved at doses which varied among different donors. Treatment of the stimulatory monocytes with ProT alpha resulted in considerably higher auto-MLR responses as compared to those with non treated monocytes. ProT alpha was without effect on T lymphocytes. In contrast, T lymphocytes exhibited enhanced proliferative activity when treated with ProT alpha in the environment of autologous monocytes. Moreover, supernatants from cultures of monocytes incubated with ProT alpha (ProT alpha-sup) were also shown to enhance the human auto-MLR either after addition in cultures or after preincubation with responder T lymphocytes. In addition, ProT alpha-sup did not demonstrate any detectable interleukin 1 (IL 1) or interleukin 2 (IL 2) - like activity. Furthermore, ProT alpha-sup induced an increase in IL 2 production in auto-MLR cultures. The enhancement of T-cell proliferation and IL 2 production by ProT alpha-sup was maximal when this material was added at the beginning of the auto-MLR, and no effect of ProT alpha-sup was seen if the latter was added 3 days after initiation of the culture. Finally, Prot alpha-sup was also shown to increase the expression of IL 2 receptors on T lymphocytes activated in the auto-MLR. These studies suggest that ProT alpha enhances the human auto-MLR through ProT alpha-sup which is released after interaction of monocytes with ProT alpha ProT alpha-sup then increases directly T lymphocyte proliferation by elevating IL 2 production and expression of IL 2 specific receptors on autoactivated T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2977606     DOI: 10.3109/08923978809006448

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  5 in total

1.  Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha.

Authors:  M Papanastasiou; C N Baxevanis; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  A standardized randomized 6-month aerobic exercise-training down-regulated pro-inflammatory genes, but up-regulated anti-inflammatory, neuron survival and axon growth-related genes.

Authors:  Osigbemhe Iyalomhe; Yuanxiu Chen; Joanne Allard; Oyonumo Ntekim; Sheree Johnson; Vernon Bond; David Goerlitz; James Li; Thomas O Obisesan
Journal:  Exp Gerontol       Date:  2015-05-15       Impact factor: 4.032

3.  Age- and sex-related differences in the content of prothymosin alpha in rat tissues.

Authors:  S Frillingos; O Tsolas
Journal:  Experientia       Date:  1992-03-15

4.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

5.  Isolation and partial sequence of goat spleen prothymosin alpha.

Authors:  S Frillingos; M Frangou-Lazaridis; K Seferiadis; J D Hulmes; Y C Pan; O Tsolas
Journal:  Mol Cell Biochem       Date:  1991-11-13       Impact factor: 3.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.